Serbest/total PSA oranı ve PSA dansitesinin prostat kanserini öngörmedeki etkinlikleri

Abstract

Giriş: Serbest/total s/t prostat spesifik antijen PSA oranı ve PSA dansitesinin PSAD tek tek ve kombine olarak prostat kanserini öngörmedeki etkinliklerinin araştırılması. Gereç ve Yöntemler: Çalışmamıza PSA değeri 2.5-10 ng/ml iken transrektal ultrasonografi eşliğinde prostat biyopsisi alınan, parmakla rektal muayene bulguları normal ve PSA düzeyini etkileyecek herhangi bir girişim, aktif enfeksiyon veya ilaç kullanım öyküsü olmayan 439 hasta dahil edildi. Tüm hastaların biyopsi öncesi total PSA, serbest PSA, yaş, prostat hacmi değerleri ve biyopsi sonrası patoloji raporları tarandı. Serbest PSA’nın sPSA total PSA’ya tPSA bölünmesiyle s/t PSA oranı ve tPSA’nın prostat hacmine bölünmesiyle PSAD elde edildi. Sınır değerler s/t PSA oranı için %20, PSAD için %15 olarak alındı. Hastalar patoloji sonucuna göre BPH ve prostat kanseri olarak iki gruba ayrıldı. Bulgular: Hastaların ortalama yaş, tPSA, sPSA, prostat hacmi, s/t PSA oranı, PSAD değerleri sırasıyla 64 ± 8.4 yıl, 6.3 ± 1.93 ng/ml, 1.28 ± 0.77 ng/ml, 56.5 ± 25.9 ml, % 20.2 ± 9.7 ve % 13.6 ± 7.5’ti. Gruplar arasında yaş p=0.311 ve tPSA p=0.691 açısından fark saptanmazken, sPSA p=0.002 , prostat hacmi p=0.001 , s/t PSA oranı p=0.002 ve PSAD p=0.001 anlamlı derecede farklı olarak bulundu. s/t PSA oranının duyarlılığı %73, özgüllüğü %45, pozitif öngörü değeri PÖD %21, negatif öngörü değeri NÖD %89 ve doğruluğu %50 olarak bulundu. PSAD’nin ise duyarlılığı %57, özgüllüğü %74, PÖD %31, NÖD %89 ve doğruluğu %71 olarak bulundu. Bu iki PSA parametresi kombine kullanıldığında duyarlılık %50, özgüllük %79, PÖD %33, NÖD %88 ve doğruluk %74 olarak saptandı. Sonuç: s/t PSA oranı ve PSAD’nin kombine olarak kullanımı, prostat kanserini öngörmede bu parametrelerin tek tek kullanımlarından daha etkilidir

Keywords

• Prostat kanseri,PSA dansitesi,s/t PSA oranı

Efficacy of percent free PSA and PSA density in the prediction of prostate cancer

Abstract

Objective: We aimed to evaluate predictive abilities of percent free prostate specific antigen PSA and PSA density PSAD in the diagnosis of prostate cancer, alone and in combination. Materials and Methods: 439 patients who had trans-rectal ultrasound guided prostate biopsy and with a PSA value between 2.5 and 10 ng/ml, normal digital rectal examination findings, and without any history of an intervention, active infection or drug use that would affect PSA levels were included in our study. All patients’ pre-biopsy total PSA tPSA , free PSA fPSA , age, prostate volume and biopsy pathology reports were reviewed. We obtained percent free PSA by dividing fPSA to tPSA and obtained PSAD by dividing tPSA to prostate volume. The cut-off value for percent free PSA was 20% and 15% for PSAD. According to pathology results, the patients were divided into two groups as BPH and prostat cancer. Results: The mean age, tPSA, fPSA, prostate volume, percent free PSA, PSAD values of the patients were; 64 ± 8.4 year, 6.3 ± 1.93 ng/ml, 1.28 ± 0.77 ng/ml, 56.5 ± 25.9 ml, 20.2% ± 9.7 and 13.6% ± 7.5, respectively. Between the two groups, fPSA p=0.002 , prostate volume p=0.000 , percent free PSA p=0.002 and PSAD p=0.001 were significantly different while age p=0.311 and tPSA p=0.691 were not. Sensitivity of percent free PSA was 73%, specificity 45%, positive predictive value PPV 21%, negative predictive value NPV 89% and accuracy 50%. Sensitivity of PSAD was 57%, specificity 74%, PPV 31%, NPV 89% and accuracy 71%. Sensitivity of using both parameters in combination was 50%, specificity 79%, PPV 33%, NPV 88% and accuracy 74%. Conclusion: In the prediction of prostate cancer, using percent free PSA and PSAD in combination is more efficient than using these parameters alone.

Keywords

• Prostate cancer,PSA density,percent free PSA

References

1. Boyle P, Ferlay J. Cancer incidence and mortality in Europe 2004. Ann Oncol 2005;16:481-8.
2. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
3. Eser S, Yakut C, Özdemir R, et al. Cancer incidence rates in Turkey in 2006: a detailed registry based estimation. Asian Pac J Cancer Prev 2010;11:1731-9.
4. Catalona WJ, Smith DS, Ratliff TL, Basler JW. Detection of organ confined prostate cancer is increased through prosta- te spesific antigen based screening. JAMA 1993;270:948-54.
5. Günay LM, Yazıcı S, Özen H. PSA nereden geldi nereye gi- diyor? Üroonkoloji Bülteni 2011;2:5-10.
6. Polascik TJ, Oesterling JE, Partin AW. Prostate specific anti- gen: a decade of discovery--what we have learned and whe- re we are going. J Urol 1999;162:293-306.
7. Catalona WJ, Southwick PC, Slawin KM, et al. Compari- son of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging. Urology 2000;56:255-60.
8. Seaman E, Whang M, Olsson CA, et al. PSA density (PSAD). Role in patient evaluation and management. Urol Clin North Am 1993;20:653-63.

9. Luderer AA, Chen YT, Soriano TF, et al. Measurement of the proportion of free to total prostate-specific antigen imp- roves diagnostic performance of prostate-specific antigen in the diagnostic gray zone of total prostate-specific antigen. Urology 1995;46:187-94.
10. Catalona WJ, Smith DS, Ratliff TL, et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991;324:1156-61.
11. Brawer MK, Chetner MP, Beatie J, et al. Screening for prostatic carcinoma with prostate specific antigen. J Urol 1992;147:841-5.
12. Morote J, Trilla E, Esquena S, et al. The percentage of free prostatic-specific antigen is also useful in men with normal digital rectal examination and serum prostatic-specific an- tigen between 10.1 and 20 ng/ml. Eur Urol 2002;42:333-7.
13. Stenman UH, Leinonen J, Alfthan H, et al. A complex bet- ween prostate-specific antigen and alpha 1-antichymotry- psin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex imp- roves clinical sensitivity for cancer. Cancer Res 1991;51:222- 6.
14. Woodrum DL, Brawer MK, Partin AW, Catalona WJ, So- uthwick PC. Interpretation of free prostate specific antigen clinical research studies for the detection of prostate cancer. J Urol 1998;159:5-12.
15. Catalona WJ, Partin AW, Slawin KM, et al. Use of the per- centage of free prostate-specific antigen to enhance differen- tiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 1998;279:1542- 7.
16. Hofer C, Sauerstein P, Wolter C, et al. Value of free prostate- specific antigen (Hybritech Tandem-R) in symptomatic pa- tients consulting the urologist. Urol Int 2000;64:18-23.
17. Pelzer AE, Volgger H, Bektic J, et al. The effect of percenta- ge free prostate-specific antigen (PSA) level on the prosta- te cancer detection rate in a screening population with low PSA levels. BJU Int 2005;96:995-8.
18. Turgut A, Yılmaz Ö, Koşar P, Koşar U. Prostat kanserinin ta- nısında TRUS eşliğinde sistematik prostat biopsisinin rolü. Yeni Üroloji Dergisi 2007;3:117-24.
19. Ustun G, Altay B, Ekren F, et al. What Kind Of Differen- ces Are There Between BPH and Prostate Cancer Regar- ding PSA And Its Derivates? Turkish Journal of Urology 2006;32:37-42.
20. Chen CS, Wang SS, Li JR, et al. PSA density as a better pre- dictor of prostate cancer than percent-free PSA in a repeat biopsy. J Chin Med Assoc 2011;74:552-5.
21. Ghafoori M, Varedi P, Hosseini SJ, Asgari M, Shakiba M. Value of prostate-specific antigen and prostate-specific anti- gen density in detection of prostate cancer in an Iranian po- pulation of men. Urol J 2009;6:182-8.
22. Akdaş A, Tarcan T, Türkeri L. The diagnostic accuracy of di- gital rectal examination, transrectal ultrasonography, pros- tate specific antigen and PSA density in prostate carcinoma. Br J Urol 1995;76:54-6.
23. Cookson MS, Floyd MK, Ball TP. The lack of predictive va- lue of prostate specific antigen density in the detection of prostate cancer in patients with normal rectal examinati- ons and intermediate prostate specific antigen levels. J Urol 1995;154:1070-3.
24. Lotfi M, Assadsangabi R, Shirazi M, et al. Diagnostic Value of Prostate Specific Antigen and Its Density in Iranian Men with Prostate Cancer. IRCMJ 2009;11:170-5.
25. Bazinet M, Meshref AW, Trudel C. Prospective evaluation of PSAD and systematic biopsies for early detection of prosta- tic carsinoma. Urology 1994;43:44-52.
26. Boulos MT, Rifkin MD, Ross J. Should prostate-specific an- tigen or prostate-specific antigen density be used as the de- termining factor when deciding which prostates should un- dergo biopsy during prostate ultrasound. Ultrasound Q 2001;17:177-80.
27. Kefi A, İrer B, Özdemir İ. Predictive value of the interna- tional prostate symptom score for positive prostate ne- edle biopsy in the low intermediate PSA range. Urol Int 2005;75:222-6.
28. Catalona WJ, Richie JP, deKernion JB, et al. Comparison of prostate specific antigen concentration versus prosta- te specific antigen density in the early detection of pros- tate cancer: receiver operating characteristic curves. J Urol 1994;152:2031-6.
29. Benson MC, McMahon DJ, Cooner WH, Olsson CA. An al- gorithm for prostate cancer detection in a patient populati- on using prostate-specific antigen and prostate-specific an- tigen density. World J Urol 1993;11:206-13.
30. Benson MC, Whang IS, Pantuck A, et al. Prostate specific antigen density: a means of distinguishing benign prosta- tic hypertrophy and prostate cancer. J Urol 1992;147:815-6.
31. Dinçel C, Caşkurlu T, Taşçi AI, et al. Prospective evaluation of prostate specific antigen (PSA), PSA density, free-to-total PSA ratio and a new formula (prostate malignancy index) for detecting prostate cancer and preventing negative biop- sies in patients with normal rectal examinations and inter- mediate PSA levels. Int Urol Nephrol 1999;31:497-509.
32. Ohori M, Dunn JK, Scardino PT. Is prostate-specific antigen density more useful than prostate-specific antigen levels in the diagnosis of prostate cancer? Urology 1995;46:666-71.
33. Gregorio EP, Grando JP, Saqueti EE, et al. Comparison bet- ween PSA density, free PSA percentage and PSA density in the transition zone in the detection of prostate cancer in pa- tients with serum PSA between 4 and 10 ng/mL. Int Braz J Urol 2007;33:151-60.
34. Stephan C, Stroebel G, Heinau M, et al. The ratio of prostate-specific antigen (PSA) to prostate volume (PSA density) as a parameter to improve the detection of prosta- te carcinoma in PSA values in the range of < 4 ng/mL. Can- cer 2005;104:993-1003.
35. Djavan B, Zlotta A, Kratzik C, et al. PSA, PSA density, PSA density of transition zone, free/total PSA ratio, and PSA ve- locity for early detection of prostate cancer in men with se- rum PSA 2.5 to 4.0 ng/mL. Urology 1999;54:517-22.